Static Chart Spyre Therapeutics, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 01:12:32 2024-05-15 pm EDT			5-day change	1st Jan Change
37.42 ^USD	-4.77%		+13.93%	+74.81%

May. 13	Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating	MT
May. 09	Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Duration

Period